Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Thyroid Cancer, Papillary × Mitoxantrone × 90 days × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1 Endocrine 1

Conditions

Leukemia, Myeloid, Acute 8 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Myelodysplastic Syndromes 2 Thyroid Cancer, Papillary 1 Recurrence 1 Prostatic Neoplasms 1 Philadelphia Chromosome 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Biphenotypic, Acute 1 Leukemia 1

Interventions

entrectinib 2 Magnetic Resonance Spectroscopy 2 tremelimumab 1 trametinib 1 selpercatinib 1 gallium Ga 68 dotatate 1 durvalumab 1 dabrafenib 1 cobimetinib 1 X-Rays 1 Vemurafenib 1 Thyrotropin Alfa 1 Surveys and Questionnaires 1 Specimen Handling 1 Mitoxantrone 1 Iodine-131 1 High-Energy Shock Waves 1 Glycoprotein Hormones, alpha Subunit 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07354698 2026-01-21

MHI

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Phase 4 Not yet recruiting

EndocrineHead & Neck

Thyroid Cancer, Papillary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡